These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18621402)

  • 1. Huntington's disease: modeling the gait disorder and proposing novel treatments.
    Banaie M; Sarbaz Y; Gharibzadeh S; Towhidkhah F
    J Theor Biol; 2008 Sep; 254(2):361-7. PubMed ID: 18621402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computational model for the Huntington disease.
    Sarbaz Y; Banae M; Gharibzadeh S
    Med Hypotheses; 2007; 68(5):1154-8. PubMed ID: 17257771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease.
    Hausdorff JM; Cudkowicz ME; Firtion R; Wei JY; Goldberger AL
    Mov Disord; 1998 May; 13(3):428-37. PubMed ID: 9613733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
    de Lago E; Urbani P; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Brain Res; 2005 Jul; 1050(1-2):210-6. PubMed ID: 15975564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lioresal in Huntington's disease.
    Paulson GW
    Dis Nerv Syst; 1976 Aug; 37(8):465-7. PubMed ID: 133792
    [No Abstract]   [Full Text] [Related]  

  • 6. [Locomotion disturbances in Huntington's disease].
    Delval A; Krystkowiak P
    Rev Neurol (Paris); 2010 Feb; 166(2):213-20. PubMed ID: 19604530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABAergic circuits in the basal ganglia and movement disorders.
    Galvan A; Wichmann T
    Prog Brain Res; 2007; 160():287-312. PubMed ID: 17499121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntington's disease: treatment with muscimol, a GABA-mimetic drug.
    Shoulson I; Goldblatt D; Charlton M; Joynt RJ
    Ann Neurol; 1978 Sep; 4(3):279-84. PubMed ID: 152602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the striatum in rule application: the model of Huntington's disease at early stage.
    Teichmann M; Dupoux E; Kouider S; Brugières P; Boissé MF; Baudic S; Cesaro P; Peschanski M; Bachoud-Lévi AC
    Brain; 2005 May; 128(Pt 5):1155-67. PubMed ID: 15788544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
    Dhir A; Akula KK; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E; Beal MF
    Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gait dysfunction in Huntington's disease: parkinsonism and a disorder of timing. Implications for movement rehabilitation.
    Churchyard AJ; Morris ME; Georgiou N; Chiu E; Cooper R; Iansek R
    Adv Neurol; 2001; 87():375-85. PubMed ID: 11347241
    [No Abstract]   [Full Text] [Related]  

  • 14. Two novel comments on the treatment of Huntington's disease.
    Gharibzadeh S; Sarbaz Y; Banaie M; Towhidkhah F
    J Neuropsychiatry Clin Neurosci; 2009; 21(1):98-9. PubMed ID: 19359460
    [No Abstract]   [Full Text] [Related]  

  • 15. A biomechanical study of gait initiation in Huntington's disease.
    Delval A; Krystkowiak P; Blatt JL; Labyt E; Bourriez JL; Dujardin K; Destée A; Derambure P; Defebvre L
    Gait Posture; 2007 Feb; 25(2):279-88. PubMed ID: 16820294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of locomotion disorders in Huntington's disease].
    Delval A; Krystkowiak P; Blatt JL; Delliaux M; Destée A; Derambure P; Defebvre L
    Neurophysiol Clin; 2008 Apr; 38(2):117-25. PubMed ID: 18423332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease.
    Manyam BV; Katz L; Hare TA; Kaniefski K; Tremblay RD
    Ann Neurol; 1981 Jul; 10(1):35-7. PubMed ID: 6455963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males.
    Bode FJ; Stephan M; Suhling H; Pabst R; Straub RH; Raber KA; Bonin M; Nguyen HP; Riess O; Bauer A; Sjoberg C; Petersén A; von Hörsten S
    Hum Mol Genet; 2008 Sep; 17(17):2595-609. PubMed ID: 18502785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: clinical and chemical effects of choline administration.
    Growdon JH; Cohen EL; Wurtman RJ
    Ann Neurol; 1977 May; 1(5):418-22. PubMed ID: 152596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake and release of GABA and GABA in Huntington's chorea [proceedings].
    Iversen LL
    Psychopharmacol Bull; 1977 Jan; 13(1):30-1. PubMed ID: 138147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.